Powered by: Motilal Oswal

News

Cipla trades higher on the BSE Cipla is currently trading at Rs. 1249.95, up by 11.40 points or 0.92% from its previous closing of Rs. 1238.55 on the BSE. The scrip opened at Rs. 1251.95 and has touched a high and low of Rs. 1266.20 and Rs. 1244.75 respectively. So far 47007 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1277.55 on 10-Aug-2023 and a 52 week low of Rs. 852.00 on 22-Mar-2023. Last one week high and low of the scrip stood at Rs...
Cipla trades higher on the BSE
Cipla trades higher on the BSE
Source: Accord Fintech
6/09/2023 1:50:50 PM
Cipla rises as its arm to acquire 100% stake in Actor Pharma Cipla is currently trading at Rs. 1241.20, up by 2.30 points or 0.19% from its previous closing of Rs. 1238.90 on the BSE. The scrip opened at Rs. 1255.90 and has touched a high and low of Rs. 1265.00 and Rs. 1238.80 respectively. So far 51953 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1277.55 on 10-Aug-2023 and a 52 week low of Rs. 852.00 on 22-Mar-2023. Last one week high and low of the scrip stood at Rs....
Cipla rises as its arm to acquire 100% stake in Actor Pharma
Cipla rises as its arm to acquire 100% stake in Actor Pharma
Source: Accord Fintech
5/09/2023 11:17:44 AM
Cipla up 3 % on reports of promoter stake sale Cipla stock price jumped more than 3 per cent on Friday after reports that Blackstone is in talks to buy out the promoter stake in the company. Last week, Cipla had clarified that the company is not aware of any event that requires disclosure under Listing Regulations. “The company will make appropriate disclosure in compliance with the Listing Regulations as and when any such requirement arises." it said in a filing. The clarification came regarding reports that ...
Cipla up 3 % on reports of promoter stake sale
Cipla up 3 % on reports of promoter stake sale
Source: IANS
4/08/2023 9:51:47 AM
Stock Picks : Cipla Ltd and Hindalco Industries Ltd By ICICI Direct Cipla Ltd Buy Cipla Ltd @1177-1179; Target 1194.00; Stop Loss 1170.60   Hindalco Industries Ltd Buy Hindalco Industries Ltd @451-452; Target 458.00; Stop Loss 448.40     To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631   Above views are of the author and not ...
Stock Picks : Cipla Ltd and Hindalco Industries Ltd By ICICI Direct
Stock Picks : Cipla Ltd and Hindalco Industries Ltd By ICICI Direct
Source: ICICI Direct
31/07/2023 11:04:57 AM
Top shareholders of India's Cipla looking to sell stake Top shareholders of Indian drugmaker Cipla are in talks to sell a part of their stake in the company to private equity players including Blackstone and Baring Asia, Moneycontrol reported on Thursday. The company is not aware of any event that requires disclosure under listing regulations, Cipla said in a exchange statement. The drugmaker's shareholders are looking to sell a part of their total 33.47% stake in the firm to strategic investors who can oversee a revamp, help enhance cap...
Top shareholders of India's Cipla looking to sell stake
Top shareholders of India's Cipla looking to sell stake
Source: Reuters
27/07/2023 3:56:41 PM
India`s Cipla jumps after Q1 profit beat Shares of Indian drugmaker Cipla rose 6% in early trading on Thursday, a day after the company reported quarterly profit that beat analyst estimates on strength in its domestic and North American drug businesses.  
India`s Cipla jumps after Q1 profit beat
India`s Cipla jumps after Q1 profit beat
Source: Reuters
27/07/2023 9:54:43 AM
Indian drugmaker Cipla posts 45% rise in Q1 profit on strong domestic business Indian pharmaceutical major Cipla reported a 45% growth in first-quarter profit on Wednesday, helped by strength in its domestic drugs business and easing input costs. Consolidated net profit for India's third-largest drugmaker by sales climbed to 9.96 billion rupees ($121.46 million) for the quarter ended June 30 from 6.86 billion rupees a year earlier. Analysts, on average, expected a profit of 8.36 billion rupees.
Indian drugmaker Cipla posts 45% rise in Q1 profit on strong domestic business
Indian drugmaker Cipla posts 45% rise in Q1 profit on strong domestic business
Source: Reuters
26/07/2023 3:31:51 PM
FPIs sold stocks worth Rs 2,081 cr in last 2 days indicating buying exhaustion In the last two days, FPIs have sold stocks worth Rs 2,081 crore indicating buying exhaustion, says V.K. Vijayakumar, Chief Investment Strategist at Geojit Financial Services. FPI flows have slowed down. This is normal response to the rising dollar index which has moved up to 101.4 from the recent low of 99. Even though Nifty is showing signs of resilience, it is unlikely to race to 20,000 level in the next few days, given the rising dollar and declining FPI inflows. Brent crude spiking to...
FPIs sold stocks worth Rs 2,081 cr in last 2 days indicating buying exhaustion
FPIs sold stocks worth Rs 2,081 cr in last 2 days indicating buying exhaustion
Source: IANS
25/07/2023 11:17:50 AM
Stock Picks : Cipla Ltd and Gujarat Gas Ltd By ICICI Direct Cipla Ltd Buy Cipla Ltd @1006-1008 CMP 1011.25; Target 1022.00; Stop Loss 1000.80   Gujarat Gas Sell Gujarat Gas Ltd @474.50-475.50 CMP 473.35; Target 468.20; Stop Loss 479.30   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631   Above vi...
Stock Picks : Cipla Ltd and Gujarat Gas Ltd By ICICI Direct
Stock Picks : Cipla Ltd and Gujarat Gas Ltd By ICICI Direct
Source: ICICI Direct
20/06/2023 11:25:24 AM
India's MedPlus Health posts two-fold surge in Q4 profit on strong sales India's MedPlus Health Services reported a two-fold surge in fourth-quarter profit on Thursday, driven by strong sales in its key retail segment. The omnichannel retail pharmacy said its consolidated net profit rose to 265.8 million rupees ($3.21 million) for the quarter ended March 31, from 117.3 million rupees a year ago. The company's consolidated revenue from operations rose 30%, thriving on the back of improved accessibility among consumers - the company sells medicines onl...
India's MedPlus Health posts two-fold surge in Q4 profit on strong sales
India's MedPlus Health posts two-fold surge in Q4 profit on strong sales
Source: Reuters
26/05/2023 9:00:35 AM
Pfizer`s India unit posts 3% rise in Q4 profit Pfizer Ltd, the Indian unit of U.S. pharmaceutical group Pfizer Inc, on Monday reported a 3.1% rise in fourth-quarter profit, helped by lower raw material expenses. Net profit for the quarter ended March 31 rose to 1.30 billion rupees ($15.90 million) from 1.26 billion rupees a year ago, while revenue rose 4.2%. Pfizer also declared a final dividend of 35 rupees per share and a special dividend of 5 rupees per share. For further earnings highlights, click: WHY IT MATTERS Pfizer...
Pfizer`s India unit posts 3% rise in Q4 profit
Pfizer`s India unit posts 3% rise in Q4 profit
Source: Reuters
16/05/2023 9:04:29 AM
Neutral Cipla Ltd For Target Rs.970 - Motilal Oswal Financial Services Regulatory issues lead to re-strategizing on niche products Work-in-progress for filing potential products from alternate sites * Cipla reported lower-than-expected performance in 4QFY23, led by higher operational cost. It achieved the highest ever annual earnings in FY23, driven by strong traction in North America (NA) sales. Cipla grew better-thanindustry in domestic formulation (DF) market by ~500bp YoY in FY23. * We cut our earnings estimates for FY24/FY25 by 7%/4% factoring in: ...
Neutral Cipla Ltd For Target Rs.970 - Motilal Oswal Financial Services
Neutral Cipla Ltd For Target Rs.970 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services
14/05/2023 10:44:41 AM
India`s Cipla posts 45% jump in Q4 profit on domestic drugs business boost Cipla Ltd, India's third-largest drugmaker by sales, reported a 45.2% increase in fourth-quarter profit on Friday, driven by strength in its key domestic and North American drugs business. Shares of the company, which manufactures generic versions of respiratory drugs Advair and Albuterol, were flat after the results but closed 0.7% lower in their second straight session of losses. Cipla's consolidated net profit jumped to 5.26 billion rupees in the quarter ended March 31 from 3...
India`s Cipla posts 45% jump in Q4 profit on domestic drugs business boost
India`s Cipla posts 45% jump in Q4 profit on domestic drugs business boost
Source: Reuters
12/05/2023 4:44:18 PM
Cipla rises on inking pact to sell 51.18% stake in Cipla Quality Chemical Industries Cipla is currently trading at Rs. 878.80, up by 6.60 points or 0.76% from its previous closing of Rs. 872.20 on the BSE. The scrip opened at Rs. 876.90 and has touched a high and low of Rs. 883.55 and Rs. 872.90 respectively. So far 36269 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1185.20 on 01-Nov-2022 and a 52 week low of Rs. 853.50 on 14-Mar-2023. Last one week high and low of the scrip stood at Rs. 896....
Cipla rises on inking pact to sell 51.18% stake in Cipla Quality Chemical Industries
Cipla rises on inking pact to sell 51.18% stake in Cipla Quality Chemical Industries
Source: Accord Fintech
15/03/2023 3:35:20 PM
Add Cipla Ltd For Target Rs.1,176 - Centrum Broking Complex gx to drive future growth Cipla reported Q3FY23 result in-line with our estimates, with overall sales grew by 6% YoY and flat QoQ to Rs 58bn, mainly driven by highest ever quarterly sales in US to US$195mn up 30% YoY led by flu seasonality benefits and traction in gLanreotide, gArformoterol, stable market share in gAlbuterol, while gRevlimid sales was lower on QoQ. Gross margin came higher at 65% on better sales mix and favorable forex. EBITDA margin came at 24% (up ~180bps YoY). A...
Add Cipla Ltd For Target Rs.1,176 - Centrum Broking
Add Cipla Ltd For Target Rs.1,176 - Centrum Broking
Source: Centrum Broking Ltd
8/03/2023 12:49:15 PM
Neutral Cipla Ltd For Target Rs.1,100 - Motilal Oswal Financial Services Niche products in North America fuel earnings growth g-Advair gets delayed further due to queries by the USFDA * CIPLA reported a miss on 3QFY23 earnings, led by a decline in SAGA/API business. Having said this, CIPLA posted the highest quarterly EBITDA margin since FY17, led by improved traction from the niche launches in North America (NA) and industry outperformance in domestic formulation (DF) * We cut our EPS estimates by 5.0%/5.5%/5.5% for FY23/FY24/FY25 to factor in: a) a dela...
Neutral Cipla Ltd For Target Rs.1,100 - Motilal Oswal Financial Services
Neutral Cipla Ltd For Target Rs.1,100 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
28/01/2023 11:28:05 AM
Cipla shines on reporting 7% rise in Q3 consolidated net profit Cipla is currently trading at Rs. 1049.90, up by 15.50 points or 1.50% from its previous closing of Rs. 1034.40 on the BSE. The scrip opened at Rs. 1028.00 and has touched a high and low of Rs. 1056.25 and Rs. 1027.40 respectively. So far 13932 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1185.20 on 01-Nov-2022 and a 52 week low of Rs. 880.00 on 24-Feb-2022. Last one week high and low of the scrip stood at Rs...
Cipla shines on reporting 7% rise in Q3 consolidated net profit
Cipla shines on reporting 7% rise in Q3 consolidated net profit
Source: Accord Fintech
27/01/2023 10:12:58 AM
India's Cipla misses Q3 profit estimates on muted domestic sales Indian drugmaker Cipla Ltd reported a smaller-than-expected rise in third-quarter profit on Wednesday, as muted sales in the domestic market offset strong demand in the North America. The Mumbai-based company's consolidated net profit for the three months ended Dec. 31, rose 9.9% to 8.01 billion rupees ($98.22 million) from 7.29 billion rupees a year ago. Analysts, on an average, had expected a profit of 9.20 billion rupees, according to Refinitiv IBES data. Cipla said sales from...
India's Cipla misses Q3 profit estimates on muted domestic sales
India's Cipla misses Q3 profit estimates on muted domestic sales
Source: Reuters
25/01/2023 6:51:05 PM
Stock of the week : Cipla Ltd For Target Rs.1248 - GEPL Capital Cipla Ltd focuses on the development of new formulations and has a wide range of pharmaceutical products. They offer prescription drugs, bulk drugs, animal products , pesticides, a wide range of food and beverages, baked foods, oral hygiene products, detergents, room fresheners and personal care products. Company drives 44% of its revenue from India, 25% North America, 15% African countries, 13% international market and 3% from API. Investment Rationale * Launching of Newer Products to ...
Stock of the week : Cipla Ltd For Target Rs.1248 - GEPL Capital
Stock of the week : Cipla Ltd For Target Rs.1248 - GEPL Capital
Source: GEPLCapital Ltd
26/12/2022 12:25:57 PM
Weekly Tech Picks: Cipla Ltd,Ashok Leyland Ltd,Tata Steel Ltd,ITC Ltd By Axis Securities Cipla Ltd • CIPLA on the weekly chart has decisively broken out above the “Multiple resistance zone” placed between 1080-1070 level on 30th Sep, 2022. • Stock had given a throwback till breakout area and forms a bullish candle at a breakout zone indicating reversal after a profit booking, 23 December, 2022reversal after a profit booking, • Stock is forming a higher high-low on the daily chart. This formation indicates a positive uptrend. • The weekl...
Weekly Tech Picks: Cipla Ltd,Ashok Leyland Ltd,Tata Steel Ltd,ITC Ltd By Axis Securities
Weekly Tech Picks: Cipla Ltd,Ashok Leyland Ltd,Tata Steel Ltd,ITC Ltd By Axis Securities
Source: Axis Securities Ltd
26/12/2022 12:05:24 PM
Cipla inches up on the BSE Cipla is currently trading at Rs. 1122.60, up by 0.10 points or 0.01% from its previous closing of Rs. 1122.50 on the BSE. The scrip opened at Rs. 1122.00 and has touched a high and low of Rs. 1147.35 and Rs. 1117.50 respectively. So far 151608 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1185.20 on 01-Nov-2022 and a 52 week low of Rs. 860.10 on 21-Jan-2022. Last one week high and low of the scrip stood at Rs...
Cipla inches up on the BSE
Cipla inches up on the BSE
Source: Accord Fintech
23/12/2022 2:38:42 PM
Neutral Cipla Ltd For Target Rs.1180 - Motilal Oswal Financial Services Efforts towards building a sustainable growth thrust * We met the management of CIPLA to understand its outlook on the business. * CIPLA is expanding its product offerings (own and in-licensing). It is recalibrating the positioning of products into Prescription, Trade Generics, and Consumer Healthcare categories in India. * Product development and approvals remain on track for differentiated launches in US Generics, which will drive growth till FY25. * Overall, we expect 18% earni...
Neutral Cipla Ltd For Target Rs.1180 - Motilal Oswal Financial Services
Neutral Cipla Ltd For Target Rs.1180 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services
19/12/2022 2:23:31 PM
Buy Cipla Ltd For Target Rs.1230 - Centrum Broking Complex gx to drive growth ahead   Cipla reported Q2FY23 result with overall sales grew by 6% YoY and 8.3% QoQ to Rs 58.3bn, led by India sales grew 6% YoY and 3% QoQ on high base (ex?Covid grew 15%  YoY). US sales grew healthy 25.6% YoY and 15.5% QoQ to US$179mn led by traction in  gLanreotide,  gRevlimid  launch  and  respiratory  products  (Albuterol,  gBrovana  and gMigranal). Gross margin was steady Y...
Buy Cipla Ltd For Target Rs.1230 - Centrum Broking
Buy Cipla Ltd For Target Rs.1230 - Centrum Broking
Source: Centrum Broking
8/12/2022 12:15:10 PM
Cipla surges on launching Leuprolide Acetate Injection Depot 22.5mg Cipla is currently trading at Rs. 1119.80, up by 18.50 points or 1.68% from its previous closing of Rs. 1101.30 on the BSE. The scrip opened at Rs. 1101.30 and has touched a high and low of Rs. 1120.20 and Rs. 1101.30 respectively. So far 8381 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1185.20 on 01-Nov-2022 and a 52 week low of Rs. 850.00 on 17-Dec-2021. Last one week high and low of the scrip stood at Rs....
Cipla surges on launching Leuprolide Acetate Injection Depot 22.5mg
Cipla surges on launching Leuprolide Acetate Injection Depot 22.5mg
Source: Accord Fintech
29/11/2022 12:09:51 PM
Buy Cipla Ltd For Target Rs.1350 - ICICI Direct Ex-Covid core growth intact; eyes on US launches… About the stock: Cipla is a global pharma company with over 1,500+ products in 65 therapeutic categories, with over 50 dosage forms. * Indian branded formulations business accounts for ~45% of revenues and enjoys leadership in therapies like respiratory, anti-infective, cardiac, gynaecology & gastro-intestinal * Cipla derives 20% of its export revenues from the US followed by 12% from South Africa, 18% from RoW markets and ...
Buy Cipla Ltd For Target Rs.1350 - ICICI Direct
Buy Cipla Ltd For Target Rs.1350 - ICICI Direct
Source: ICICI Direct Ltd
21/11/2022 11:03:38 AM
Hold Cipla Ltd For Target Rs.1091 - ICICI Securities US drives beat; upside priced in Cipla’s Q2FY23 performance was ahead of our estimates on reported front but adjusting for Revlimid sales it was broadly in-line. Revenue grew 5.6% YoY to Rs58.3bn (I-Sec: Rs.55.5bn) driven by strong uptick in US revenue (US$179mn, +15.5% QoQ) which partially benefitted from the launch of Revlimid. Adj. EBITDA margin (ex-covid inventory write-off) expanded 160bps YoY (+260bps QoQ) to 23.8% (I-Sec: 21%). Adjusted PAT was up 17.4% YoY to Rs8.3bn. Company...
Hold Cipla Ltd For Target Rs.1091 - ICICI Securities
Hold Cipla Ltd For Target Rs.1091 - ICICI Securities
Source: ICICI Securities Ltd
9/11/2022 2:40:32 PM
India`s Cipla beats estimates with 11% rise in quarterly profit Indian drugmaker Cipla reported a better-than-expected 11% rise in second-quarter profit on Friday, as revenue from new ventures almost doubles. Consolidated net profit rose to 7.89 billion Indian rupees ($95.6 million) in the quarter, from 7.11 billion rupees a year ago. Analysts, on average, expected the company to report a profit of 7.83 billion rupees, according to Refinitiv data. Cipla's total revenue from operations rose 5% to 57.59 billion rupees. ($1 = 82.5010 Indian rupe...
India`s Cipla beats estimates with 11% rise in quarterly profit
India`s Cipla beats estimates with 11% rise in quarterly profit
Source: Reuters
4/11/2022 3:06:35 PM
Stock Picks - Cipla Ltd And Tata Motors Ltd By ICICI Direct Cipla Ltd Buy Cipla Ltd Ltd @ 1165.00-1168.00 CMP 1165.90 Stop Loss 2665.20 Target 1176.00/1185.00   Tata Motors Ltd Buy Titan Compamy Ltd @ 1165.00-1168.00 CMP 1165.90 Stop Loss 1155.70 Target 1176.00/1185.00   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Regis...
Stock Picks - Cipla Ltd And Tata Motors Ltd By ICICI Direct
Stock Picks - Cipla Ltd And Tata Motors Ltd By ICICI Direct
Source: ICICI Direct
28/10/2022 11:38:33 AM
Diwali Muhurat Technical Picks: Underlying Strategy By Axis Securities We have handpicked a few stocks for buying this Diwali that have given breakouts and showing strong accumulation patterns on the medium and longer-term charts. We have covered Large Caps as well as Mid Cap stocks that have performed in line with the market trend over the last one year and are now trading above their breakout levels. A few of them are at their major support levels. We advise accumulating these stocks in the recommended buying range to cover the downside risks and corrections i...
Diwali Muhurat Technical Picks: Underlying Strategy By Axis Securities
Diwali Muhurat Technical Picks: Underlying Strategy By Axis Securities
Source: Axis Securities Ltd
21/10/2022 10:32:51 AM
Buy Cipla Ltd For Target Rs.1135 - ICICI Direct About the stock: Cipla is a global pharma company with over 1,500+ products in 65 therapeutic categories, with over 50 dosage forms. * Indian branded formulations business accounts for ~45% of revenues and enjoys leadership in therapies like respiratory, anti-infective, cardiac, gynaecology & gastro-intestina * Cipla derives 20% of its export revenues from the US followed by 12% from South Africa, 18% from RoW markets and 3% from APIs Q1FY23 Results: Revenues were in-line with I-...
Buy Cipla Ltd For Target Rs.1135 - ICICI Direct
Buy Cipla Ltd For Target Rs.1135 - ICICI Direct
Source: ICICI Direct Ltd
10/10/2022 3:33:43 PM
Cipla moves up on getting EIR from USFDA for Indore plant Cipla is currently trading at Rs. 1071.00, up by 9.30 points or 0.88% from its previous closing of Rs. 1061.70 on the BSE. The scrip opened at Rs. 1065.00 and has touched a high and low of Rs. 1092.80 and Rs. 1065.00 respectively. So far 28305 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1101.00 on 21-Sep-2022 and a 52 week low of Rs. 850.00 on 17-Dec-2021. Last one week high and low of the scrip stood at Rs....
Cipla moves up on getting EIR from USFDA for Indore plant
Cipla moves up on getting EIR from USFDA for Indore plant
Source: Accord Fintech
23/09/2022 11:03:30 AM
Stock Picks - Hindustan Unilever Ltd and Cipla Ltd By ICICI Direct Hindustan Unilever Ltd Buy Hindustan Unilever Ltd @ 2605-2608 CMP 2623.60 Stop Loss 2580.40 Target 2633.2/2659.7   Cipla Ltd Buy Cipla Ltd @ 1058-1060 CMP 1070.40 Stop Loss 1048.40 Target 1069.30/1079.80     To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631   Above views are of t...
Stock Picks - Hindustan Unilever Ltd and Cipla Ltd By ICICI Direct
Stock Picks - Hindustan Unilever Ltd and Cipla Ltd By ICICI Direct
Source: ICICI Direct
22/09/2022 10:35:21 AM
Stock Picks - Cipla Ltd and Hero Motocorp Ltd By ICICI Direct Cipla Ltd Buy Cipla Ltd@1042.00-1044.00 CMP 1043.50Stop Loss1032.70 Target 1053.30/1063.801   Hero Motocorp Ltd Buy Hero Motocorp Ltd@2685.00-2690.00 CMP 2685.20Stop Loss2714.40 Target 2660.60/2633.30   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631   Above vi...
Stock Picks - Cipla Ltd and Hero Motocorp Ltd By ICICI Direct
Stock Picks - Cipla Ltd and Hero Motocorp Ltd By ICICI Direct
Source: ICICI Direct
19/09/2022 11:29:24 AM
Weekly Tech Picks -Sumitomo Chemical India Ltd, Cipla Ltd, Bharat Dynamics Ltd,Voltas Limited(Future) By Axis Securities Sumitomo Chemical India Limited • On the daily time frame, the stock has observed “cup & handle” breakout around 518 levels along with huge volumes • The stock is well placed above its 20,50,100 and 200 Day SMA’s which reconfirm bullish sentiments • The daily “band Bollinger” buy signal 16 September,2022indicate increased momentum • The daily and weekly strength indicator RSI is in positive terrain and sustaining above 9EMA mar...
Weekly Tech Picks -Sumitomo Chemical India Ltd, Cipla Ltd, Bharat Dynamics Ltd,Voltas Limited(Future) By Axis Securities
Weekly Tech Picks -Sumitomo Chemical India Ltd, Cipla Ltd, Bharat Dynamics Ltd,Voltas Limited(Future) By Axis Securities
Source: Axis Securities Ltd
18/09/2022 3:40:54 PM
Stock Picks - Cipla Ltd and Britannia Industries Ltd By ICICI Direct Cipla Ltd Buy Cipla Ltd@1046.00-1048.00 CMP 1058.90Stop Loss1036.70 Target 1057.00/1068.00   Britannia Industries Ltd Buy Britannia Industries Ltd@3718.00-3724.00 CMP 3757.70Stop Loss3687.30 Target 3751.00/3781.00   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631  ...
Stock Picks - Cipla Ltd and Britannia Industries Ltd By ICICI Direct
Stock Picks - Cipla Ltd and Britannia Industries Ltd By ICICI Direct
Source: ICICI Direct
14/09/2022 12:54:16 PM
Neutral Cipla Ltd For Target Rs.950 - Motilal Oswal Financial Services Pipeline build-up on track in the Respiratory and Peptide space One-India strategy driving steady industry outperformance * CIPLA delivered a better-than-expected 1QFY23 performance, led by healthy traction in the US and emerging markets, and controlled cost. The strategy of ‘One-India’ (prescription, trade generics, and consumer health) as well as building a Complex Respiratory and Peptide pipeline in the US Generics is progressing well to cater to better business prospects...
Neutral Cipla Ltd For Target Rs.950 - Motilal Oswal Financial Services
Neutral Cipla Ltd For Target Rs.950 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
12/09/2022 10:45:02 AM
Cipla jumps on receiving USFDA`s approval for Lenalidomide Capsule Cipla is currently trading at Rs. 1058.60, up by 17.90 points or 1.72% from its previous closing of Rs. 1040.70 on the BSE. The scrip opened at Rs. 1038.10 and has touched a high and low of Rs. 1061.55 and Rs. 1035.10 respectively. So far 48969 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1083.15 on 15-Mar-2022 and a 52 week low of Rs. 850.00 on 17-Dec-2021. Last one week high and low of the scrip stood at Rs...
Cipla jumps on receiving USFDA`s approval for Lenalidomide Capsule
Cipla jumps on receiving USFDA`s approval for Lenalidomide Capsule
Source: Accord Fintech
7/09/2022 3:20:36 PM
Stock Picks - Asian Paints Ltd and Cipla Ltd By ICICI Direct Asian Paints Ltd Buy Asian Paints Ltd @3378.00-3384.00 CMP 3395.25 Stop Loss 3352.30 Target 3408.00/3435.00 Cipla Ltd Buy Cipla Ltd @1031.00-1034.00 CMP 1040.85 Stop Loss 1021.30 Target 1043.00/1053.00   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number I...
Stock Picks - Asian Paints Ltd and Cipla Ltd By ICICI Direct
Stock Picks - Asian Paints Ltd and Cipla Ltd By ICICI Direct
Source: ICICI Direct
7/09/2022 11:52:12 AM
Add Cipla Ltd For Target Rs.1,040 - Centrum Broking In-line quarter; complex gx to drive growth ahead Cipla reported Q1FY23 result with overall sales declined 2.3% YoY to Rs 53.7 bn, led by India sales declined 8% YoY on high base (ex-Covid grew 9% YoY). US sales declined 3% QoQ to USD 155 mn (+10% YoY) by traction in gLanreotide and respiratory products (Albuterol, gBrovana and gMigranal). Gross margin was steady YoY at 62% on better sales mix. Muted staff (4% YoY) and other expenses (8% YoY) led to EBITDA of Rs 11.4 bn (-15% YoY on high C...
Add Cipla Ltd For Target Rs.1,040 - Centrum Broking
Add Cipla Ltd For Target Rs.1,040 - Centrum Broking
Source: Centrum Broking Ltd
6/09/2022 3:56:01 PM
Stock Picks - Asian Paints Ltd and Cipla Ltd By ICICI Direct  Asian Paints Ltd Buy Asian Paints Ltd@3380.00-3384.00 CMP 3391.60 Stop Loss 3351.30 Target 3411.00/3438.00   Cipla Ltd ??????? Buy Cipla Ltd@1023.00-1026.00 CMP1038.45 Stop Loss 1014.20 Target 1035.70/1046.00   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registrati...
Stock Picks - Asian Paints Ltd and Cipla Ltd By ICICI Direct
Stock Picks - Asian Paints Ltd and Cipla Ltd By ICICI Direct
Source: ICICI Direct
1/09/2022 1:05:49 PM
Neutral Cipla Ltd For Target Rs.950 - Motilal Oswal Financial Services Enhanced effort required to improve return ratios going forward * Our Annual Report analysis of Cipla indicates robust improvement in return ratios over FY18-22. Notably, there had been an improvement in ROE in FY21 (+400bp YoY) to 14.1% and it sustained at similar levels in FY22. * Over FY18-20, Cipla’s earnings were largely flat. However, the efforts across key geographies aided by limited competition products in the US generics, COVID (FY21), and cost optimization measures led ...
Neutral Cipla Ltd For Target Rs.950 - Motilal Oswal Financial Services
Neutral Cipla Ltd For Target Rs.950 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
19/08/2022 8:49:19 AM
Key News - Bajaj Finserv Ltd, Nestle India Ltd, Cipla Ltd, Shree Cement Ltd, Oil and Natural Gas Corporation Ltd, Adani Capital Ltd By ARETE Securities Key News Bajaj Finserv surges 10% after board approves 1:1 bonus, 1:5 stock split Shares of Bajaj Finserv surged 10 per cent to Rs 14,579.95 on the BSE in Thursday’s intra-day trade after the company’s board approved 1:1 bonus issue and 1:5 stock split. On July 28, 2022, the board approved sub-division of each existing equity share of face value of Rs 5 into five equity shares of face value of Rs 1 fully paid- up. The board also approved issue of one bonus equity shares of f...
Key News - Bajaj Finserv Ltd, Nestle India Ltd, Cipla Ltd, Shree Cement Ltd, Oil and Natural Gas Corporation Ltd, Adani Capital Ltd By ARETE Securities
Key News - Bajaj Finserv Ltd, Nestle India Ltd, Cipla Ltd, Shree Cement Ltd, Oil and Natural Gas Corporation Ltd, Adani Capital Ltd By ARETE Securities
Source: ARETE Securities Ltd
29/07/2022 9:31:45 AM
Buy Cipla Ltd For Target Rs.1,015 - Religare Broking   Religare Super Idea**   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://www.religareonline.com/disclaimer SEBI Registration number is INZ000174330   Views express by all participants are for information & academic purpose only. Kindly read disclaimer before referring below views. Click Here For Disclaimer  
Buy Cipla Ltd For Target Rs.1,015 - Religare Broking
Buy Cipla Ltd For Target Rs.1,015 - Religare Broking
Source: Religare Broking Ltd
21/07/2022 9:44:15 AM
Cipla inches up as its arm inks definitive agreements to acquire Endura Mass Cipla is currently trading at Rs. 953.60, up by 2.75 points or 0.29% from its previous closing of Rs. 950.85 on the BSE. The scrip opened at Rs. 967.40 and has touched a high and low of Rs. 967.40 and Rs. 951.90 respectively. So far 2545 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1083.15 on 15-Mar-2022 and a 52 week low of Rs. 850.00 on 17-Dec-2021. Last one week high and low of the scrip stood at Rs. 968.3...
Cipla inches up as its arm inks definitive agreements to acquire Endura Mass
Cipla inches up as its arm inks definitive agreements to acquire Endura Mass
Source: Accord Fintech
15/07/2022 9:59:53 AM
SBI Healthcare Opportunities Fund: change in investment factsheets for June 2022 SBI Healthcare Opportunities Fund has announced change in investment factsheets and fund flash for the month ended June 30, 2022. As on Jun 30, 2022, the total size of the Fund was Rs 1,589.63 crores, compared with Rs 1,638.30 crores in the last month. The Fund's NAV per unit was Rs 205.60 for Growth, while 52-Week High and Low ranges were Rs 239.18 and Rs 194.21 respectively. The Equity - Sector Fund fund with Growth plan was launched on Jul 14, 1999 and managed by Fund Manager Tanmaya D...
SBI Healthcare Opportunities Fund: change in investment factsheets for June 2022
SBI Healthcare Opportunities Fund: change in investment factsheets for June 2022
Source: Dion Global Solutions Ltd
14/07/2022 10:45:03 AM
Cipla inches up on signing definitive agreements for acquisition of 21.05% stake in Achira Labs Cipla is currently trading at Rs. 917.10, up by 1.50 points or 0.16% from its previous closing of Rs. 15.60 on the BSE. The scrip opened at Rs. 915.60 and has touched a high and low of Rs. 918.10 and Rs. 901.95 respectively. So far 3438 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1083.15 on 15-Mar-2022 and a 52 week low of Rs. 850.00 on 17-Dec-2021. Last one week high and low of the scrip stood at Rs. 984.05...
Cipla inches up on signing definitive agreements for acquisition of 21.05% stake in Achira Labs
Cipla inches up on signing definitive agreements for acquisition of 21.05% stake in Achira Labs
Source: Accord Fintech
20/06/2022 9:39:23 AM
Cipla shines on adding capacity of captive renewable energy power plant in Maharashtra, Karnataka Cipla is currently trading at Rs. 1003.20, up by 20.05 points or 2.04% from its previous closing of Rs. 983.15 on the BSE. The scrip opened at Rs. 989.90 and has touched a high and low of Rs. 1006.85 and Rs. 977.05 respectively. So far 8034 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1083.15 on 15-Mar-2022 and a 52 week low of Rs. 850.00 on 17-Dec-2021. Last one week high and low of the scrip stood at Rs. 10...
Cipla shines on adding capacity of captive renewable energy power plant in Maharashtra, Karnataka
Cipla shines on adding capacity of captive renewable energy power plant in Maharashtra, Karnataka
Source: Accord Fintech
2/06/2022 10:11:09 AM
Stock Picks - Cipla Ltd and DLF Ltd By ICICI Direct Cipla Ltd Buy Cipla Ltd @ 944.00-947.00 CMP 956.85 Stop Loss 937.70 Target 954.00/962.00   DLF Ltd Sell DLF Ltd @ 322.00-324.00 CMP 324.65 Stop Loss 326.10 Target 320.10/317.00   To Read Complete Report & Disclaimer Click Here   https://secure.icicidirect.com/Content/StaticData/Disclaimer.html   Above views are of the author and not of the website kindly read disclaim...
Stock Picks - Cipla Ltd and DLF Ltd By ICICI Direct
Stock Picks - Cipla Ltd and DLF Ltd By ICICI Direct
Source: ICICI Direct
19/05/2022 9:52:10 AM